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Worldwide, pneumonia affects 156 million children aged <5 years old every year, and it is the leading cause of mortality in this age group [1]. More than 2 million 
annual deaths are estimated to occur because of pneumonia in 
<5 years old and almost all of these occur in the developing 
world. In India, 43 million cases and 0.4 million deaths are due 
to the pneumonia. The median incidence of pneumonia in India is 
estimated to be 0.37 episodes per child per year [2].
Studies in developing countries have suggested an association 
between nutritional rickets and pneumonia. There were 13-fold 
higher incidences of rickets among children with pneumonia 
than among controls in Ethiopian children [3]. Furthermore, 
low Vitamin D status was found to be an independent risk factor 
for treatment failure and for prolonged severe lower respiratory 
infection in a study on Nepalese children [4]. Vitamin D 
deficiency was also found to be significantly associated with 
children admitted to the pediatric intensive care unit with severe 
acute lower respiratory infection [5].
1,25-dihydroxy Vitamin D, the active form of Vitamin D 
activates Vitamin D receptor which induces antimicrobial peptides 
(cathelicidin and β-defensin 2). These are vanguards of innate 
immune responses against bacterial, fungal, and viral pathogens. 
Furthermore, the susceptibility to infection occurs before many of 
the overt manifestations of the nutritional rickets might occur [6]. 
Studies have shown an association of subclinical Vitamin D 
deficiency with severe acute lower respiratory infection [7,8]. 
Hence, an intervention of Vitamin D supplementation in resource 
poor settings might help in reducing the disease burden of 
pneumonia in the community. However, in spite of these evidence, 
there are very few studies done on Vitamin D supplementation in 
children with pneumonia [9,10]. Hence, we conducted this trial 
to test whether Vitamin D supplementation in under-5 children 
presenting with pneumonia and severe pneumonia reduces its 
duration and its recurrences.
METHODS
This double-blind, placebo-controlled, randomized trial was 
conducted on children between 2 months and 5 years with 
diagnosis of pneumonia and severe pneumonia admitted in 
pediatric unit of a teaching institute in north Karnataka during 
December 2014 to November 2015 over a period of 1 year. Prior 
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approval of institutional ethical committee was taken. Written 
informed consent was taken from either of the parents before 
recruitment.
Pneumonia was diagnosed (as per the WHO definition) 
in children presenting with cough, cold, and fast breathing 
(respiratory rate ≥50 per min in 2 months–12 months; 
≥40 per min in 12 months–5 years). Children presenting with 
chest in drawing along with the above symptoms were diagnosed 
as severe pneumonia [11]. Children with clinical features of 
rickets (craniotabes, frontal bossing, rachitic rosary, Harrison 
groove, enlargement of wrist, and ankle), severe malnutrition 
(weight for height/length < −3 SD, with or without edema, and 
with or without midupper arm circumference <11.5 cm), history 
suggestive of asthma, underlying disorders (cough >2 weeks, 
tuberculosis, congenital heart diseases, retroviral disease, epilepsy, 
nephrotic syndrome, and bleeding disorder), and any Vitamin D 
supplementation over the past 12 months were excluded from the 
study.
Subjects were randomized into two groups according to a 
computer generated random number table. Group allocation 
was concealed in a brown opaque envelope. Intervention group 
(Group I) received 1 ml (300,000 IU Vitamin D3, Abbott India 
Limited) of Vitamin D intramuscularly, and the control group 
(Group II) received 1 ml of sterile water as a placebo over the 
lateral aspect of thigh, using 2cc disposable syringe with 24 
number needle. The attached labels of the ampoules of Vitamin D3 
and sterile water were removed, so they appeared similar and 
were given a unique identity number which was sealed by the 
pharmacist not aware of the groups. The identity was opened 
after the intervention, data collection, follow-up, and tabulation 
were completed. The ampoules were stored in a dry and cool 
environment according to the manufacturer’s recommendations. 
The investigators and the caretakers of the subjects were unaware 
of the study groups.
Both the groups received antibiotics in the form of intravenous 
Penicillin G (200,000 units/kg/day in four divided doses) and 
supportive care in the form of oxygen, intravenous fluids, and 
antipyretics (paracetamol at 15 mg/kg/dose).
Detail history, demographic data, socioeconomic status 
(Kuppuswamy’s socioeconomic status scale modified for 
2007 [12]), immunization status, history of breastfeeding and 
complementary feeding practice, exposure to smoking, type of 
fuel used for cooking (liquefied petroleum gas [LPG]/non-LPG), 
and housing conditions were recorded in a structured pro forma. 
Clinical examination including anthropometry as per the standard 
techniques was also recorded. Respiratory rate was recorded for 
one full minute for 2 times after removing all the clothes when 
the child was awake and not crying. Axillary temperature was 
checked using digital thermometer with standard technique. 
Venous blood was drawn for hemoglobin, blood counts, serum 
calcium, and alkaline phosphatase and for blood culture (which 
was collected separately under all aseptic precautions). Chest 
radiograph was done in all the children and was reported by a 
qualified radiologist, not aware of the study groups.
All the children were clinically monitored and details of the 
pulse rate, respiratory rate, temperature, chest indrawing, feeding, 
and general condition were recorded every 8 h. Persistence for 
more than 48 h or worsening of the above-mentioned signs was 
considered as deterioration or failure to treat. In such cases, 
antibiotics were stepped up to cefotaxime (50 mg/kg/dose every 
8 h intravenously). Improvement of tachypnea, fever, and chest 
indrawing persisting for ≥48 h was considered as recovery, after 
which the child was discharged. The duration of resolution was 
recorded from the time of study enrolment to that of recovery. All 
the children were given an identity card and were followed-up for 
120 days after discharge for any repeat episodes of pneumonia.
All the children fulfilling the study criteria were included in 
the study over the period of 1 year of the study. Collected data 
were presented in percentage and proportions. Chi-square test 
was used to see the association, and t-test or non-parametric test 
was used to see the difference between two variables.
RESULTS
During the study period, 106 children were enrolled. Of which, 26 
children were excluded as 13 lost to follow-up (7 in intervention 
group and 6 in placebo group), 11 parents refused consent, and 2 
detected to have pulmonary tuberculosis (Fig. 1). Hence, results 
were analyzed for 80 children with 40 in each group.
Both the groups were comparable with respect to age, sex, 
low birth weight and preterm at birth, education of the parents, 
exposure to smoking, type of fuel used, overcrowding, and 
socioeconomic status (Table 1). Both the groups were similar 
with respect to previous history of pneumonia, nutritional status 
(weight for height), and presence of anemia (hemoglobin<11 g/dL) 
(Table 2). 24 (60%) children out of 40 in intervention group and 
26 (65%) out of 40 in placebo group presented with pneumonia 
and the remaining (16 [40%] and 14 [35%], respectively) children 
presented with severe pneumonia (p>0.05). Hence, severity of 
pneumonia was also equally distributed between the two groups 
as difference was not statistically significant.
Chest radiograph showed the features of consolidation 
in 15 (37.5%) and 11 (27.5%) in intervention and placebo, 
respectively (p>0.05). Blood culture was positive in 1 (2.5%) and 
2 (5%) in intervention and placebo groups, respectively (p>0.05). 
Both the groups were comparable with respect to radiological and 
microbiological parameters as the difference was not significant.
Most of the children in both the groups responded to 
Penicillin G. Antibiotics were stepped up to cefotaxime in 
3 (7.5%) children of intervention group and 4 (10%) children of the 
control group. Time to resolution of symptoms (fever, tachypnea, 
and chest retractions) was almost similar (3.63±1.27 days in 
intervention group and 3.6±0.78 days in placebo group, p=0.933) 
and was not significant. On follow-up of these children, recurrence 
of pneumonia was significantly high in placebo group (20 [40%] 
in placebo group vs. 3 [7.5%] in intervention group, p<0.05). 
Risk of recurrence was 0.201 (95% confidence interval, 0.069–
0.587) in the intervention group. All the children responded to 
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the treatment, and none of them developed complications of 
pneumonia or adverse effects of Vitamin D toxicity.
DISCUSSION
This well-conducted double-blind, placebo-control, randomized 
trial shows that supplementation with Vitamin D along with 
antibiotics in children with pneumonia and severe pneumonia 
significantly reduces the risk of recurrence over the period of 
3 months. However, it has no effect on the duration of recovery of 
the present episode of pneumonia.
The major limitation of our study was the small sample size, 
as we included children with pneumonia and severe pneumonia 
over the period of 12 months. Other limitation was we could 
not do serum levels of Vitamin D in our subjects before or after 
supplementation due to financial constraints. Furthermore, 
we could not identify the viral causes of pneumonia due to the 
non-availability of the facility; however, it would be equally 
distributed between the two groups.
The factors associated with pneumonia (birth weight, gestation, 
immunization status, breastfeeding, exposure to passive smoking, 
type of fuel used at home, anemia, socioeconomic status, housing 
conditions, and parental education) were equally distributed 
between the two groups. These were the modifiable risk factors 
associated with children aged between 1 month and 5 years 
presenting with pneumonia in an Indian study by Savitha et al. 
[13]. We excluded children with severe malnutrition as they would 
be supplemented with micronutrients as a part of the management. 
Children in our study had no clinical signs of Vitamin D deficiency 
and hence many not receive any Vitamin D supplementation. 
However, subclinical Vitamin D deficiency can be a significant 
Table 1: Baseline characteristics of the groups*
Parameter Intervention 
group n (%)
Placebo 
group n (%)
Age
2–12 months 19 (47.5) 22 (55)
12 months–5 years 21 (52.5) 18 (45)
Boys 22 (55) 26 (65)
Parental education
Illiterate 8 (20) 9 (22.5)
Preterm birth 7 (17.5) 5 (12.5)
Low birth weight (<2.5 kg) 4 (10) 3 (7.5)
Immunization status
Complete 32 (80) 34 (85)
Partial 8 (20) 6 (15)
Previous episode of pneumonia 4 (10) 3 (7.5)
Exclusive breastfeeding 29 (72.5) 32 (80)
Exposure to passive smoking 5 (12.5) 7 (17.5)
Type of fuel used
Non-LPG 22 (55) 22 (55)
Overcrowding # 20 (50) 18 (45)
Socioeconomic status
Middle (Class III) 9 (27.5) 11 (27.5)
Lower (Class IV, V) 31 (77.5) 29 (72.5)
*p>0.05, overcrowding: >2 persons per room, >3 persons per 2 rooms, >5 persons 
per 3 rooms [12]
Figure 1: Flow diagram
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risk factor for severe acute lower respiratory infection as shown 
by Wayse et al. in Indian children [7]. Furthermore, susceptibility 
to infection occurs before many of the overt manifestations of 
nutritional rickets might appear [14]. Our study adds further 
evidence of Vitamin D supplementation playing a potential role 
in protecting from recurrences of respiratory tract infection which 
may be due to the underlying subclinical Vitamin D deficiency.
There were no gross side effects (nausea, vomiting, abdominal 
pain, constipation, and poor feeding) detected after giving such 
a high dose (300,000 IU) of Vitamin D by intramuscular route. 
Study on children in Istanbul (aged 6–30 months) treated with 
the same dose of Vitamin D for rickets was found to be safe and 
effective [15]. We chose to give Vitamin D as a single dose instead 
of daily or intermittent dosage due to the concerns of compliance 
and its effectiveness in maintaining the serum Vitamin D levels 
over 2–3 months as evident in previous studies [10]. A study in 
Kabul showed that supplementation with quarterly bolus doses of 
Vitamin D (100,000 IU) did not affect the incidence or severity 
of the pneumonia in infants [16]. Furthermore, reliability of 
intermittent dosing was poor because of wide variability in the 
serum Vitamin D concentration achieved. Studies have shown that 
single oral dose led to rapid peak followed by fall of Vitamin D 
concentration; however, single intramuscular dose led to long-
lasting serum Vitamin D levels even though it sometimes took 
nearly 2 months to achieve the peak concentration and which 
remained higher for almost a year [17].
The follow-up duration of 3 months in our study though short 
was appropriate to assess the effect of supplementation. Studies 
show that it takes nearly 2months for the peak concentration of 
vitamin D to be achieved after receiving single intramuscular 
large dose [17]. This might also be the reason why Vitamin 
D supplementation in our study did not reduce the duration 
of the current episode of pneumonia. This was also evident in 
previous studies by Choudhary et al. on Indian children [9] and 
by Manaseki-Holland et al. in Kabul [10]. The possible cause 
might be blood levels of Vitamin D might still be suboptimal 
immediately after the administration of the dose for the effect to 
occur.
Even though India is located in tropical region with abundant 
sunlight, Vitamin D deficiency is common. Several studies 
in South Asian population have reported high prevalence of 
hypovitaminosis D, despite living in areas with abundant 
ultraviolet B radiation. Sun-avoidant behavior leaves many 
dependent on diets for intake of Vitamin D, which are inadequate 
in fulfilling Vitamin D requirements [14]. The average adult 
diet typically provides <10–20% of an individual’s Vitamin D 
stores which in a child’s diet is likely to provide even lesser [18]. 
Breastfeeding may not provide enough Vitamin D for infants, 
especially if mothers are also Vitamin D deficient [7,8,19]. 
The complementary or replacement foods in the diets of Indian 
infants and children are not fortified with Vitamin D [7]. Hence, 
supplementation with Vitamin D remains the most appropriate 
option available.
However, risk of hypervitaminosis D should be kept in mind, 
hence, measuring the levels of Vitamin D before supplementing 
wherever possible would be a more rational practice. At present, 
due to non-availability of an optimal Vitamin D supplementation 
regime for skeletal or immunological functions of Vitamin D [20], 
more studies are needed in different settings using different dosages 
with a large sample size. Furthermore, there is a scope for studies 
on Vitamin D supplementation in other childhood infections.
CONCLUSION
Our study shows that supplementation of single high dose 
(300,000 IU) of Vitamin D given intramuscularly significantly 
reduces the recurrence of pneumonia. The present study further 
strengthens the evidence of Vitamin D supplementation in 
pneumonia which is responsible for the highest burden of childhood 
mortality and morbidity worldwide. This has an importance from 
a public health point of view in resource poor settings as a simple 
measure of supplementing high dose of Vitamin D (300,000 IU) 
during the episode of pneumonia reduces the risk of recurrence 
which would help to reduce the disease burden and mortality.
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